In one paragraphArticle in PLoS genetics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from itWhat it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
5 · Who and what moneyAuthors and funding
8 authors.
Corinne A McCoyDepartment of Cellular and Molecular Medicine, Department of Medicine, Division of Genomics and Precision Medicine, Moores Cancer Center, and Institute for Genomic Medicine, UC San Diego School of Medicine, La Jolla, California, United States of America.ORCID https://orcid.org/0000-0001-8960-414X Dorothy ConcepcionDepartment of Cellular and Molecular Medicine, Department of Medicine, Division of Genomics and Precision Medicine, Moores Cancer Center, and Institute for Genomic Medicine, UC San Diego School of Medicine, La Jolla, California, United States of America.
Mark G MezodyDepartment of Cellular and Molecular Medicine, Department of Medicine, Division of Genomics and Precision Medicine, Moores Cancer Center, and Institute for Genomic Medicine, UC San Diego School of Medicine, La Jolla, California, United States of America.ORCID https://orcid.org/0009-0009-0071-9852 Raquel Z LaraDepartment of Cellular and Molecular Medicine, Department of Medicine, Division of Genomics and Precision Medicine, Moores Cancer Center, and Institute for Genomic Medicine, UC San Diego School of Medicine, La Jolla, California, United States of America.ORCID https://orcid.org/0000-0003-3769-9313 Ojas DeshpandeDepartment of Cellular and Molecular Medicine, Department of Medicine, Division of Genomics and Precision Medicine, Moores Cancer Center, and Institute for Genomic Medicine, UC San Diego School of Medicine, La Jolla, California, United States of America.ORCID https://orcid.org/0000-0002-6029-2370 Catherine LiangDepartment of Cellular and Molecular Medicine, Department of Medicine, Division of Genomics and Precision Medicine, Moores Cancer Center, and Institute for Genomic Medicine, UC San Diego School of Medicine, La Jolla, California, United States of America.ORCID https://orcid.org/0009-0009-4808-514X Renee LongDepartment of Cellular and Molecular Medicine, Department of Medicine, Division of Genomics and Precision Medicine, Moores Cancer Center, and Institute for Genomic Medicine, UC San Diego School of Medicine, La Jolla, California, United States of America.ORCID https://orcid.org/0000-0003-1638-3459 Bruce A HamiltonDepartment of Cellular and Molecular Medicine, Department of Medicine, Division of Genomics and Precision Medicine, Moores Cancer Center, and Institute for Genomic Medicine, UC San Diego School of Medicine, La Jolla, California, United States of America.ORCID https://orcid.org/0000-0001-5599-9139 Funding
VIRAL MALIGNANCYP30CA023100 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI DIANE M SIMEONE · 1985 to 2026
$124.9MTransgenic & Knock-out MouseP30DK063491 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI PETER J TONTONOZ · 2003 to 2026
$40.4MMentoring Young Minds to Increase Diversity in the Biomedical ResearchR25GM083275 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI DE MAIO, ANTONIO, LAWSON, MARK ANDREW · 2008 to 2022
$9.9MU of Calif, San Diego Neuroscience Microscopy ImagingP30NS047101 · NINDS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI GLEESON, JOSEPH G, ZHENG, BINHAI · 2003 to 2022
$9.0MPredoctoral and Postdoctoral Training in Cancer Cell BiologyT32CA067754 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI JEAN Y.J. WANG · 1995 to 2026
$6.5MZfp423 Mechanisms in Joubert Syndrome and Related DisordersR01NS097534 · NINDS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI BRUCE A HAMILTON · 2017 to 2026
$4.5MNCI NIH HHS P30 CA023100NCI NIH HHS T32 CA067754NIDDK NIH HHS P30 DK063491NIGMS NIH HHS R25 GM083275NINDS NIH HHS P30 NS047101NINDS NIH HHS R01 NS097534
6 · The paper itselfAbstract
Tubby-like protein 3 (TULP3) regulates receptor trafficking in primary cilia and antagonizes SHH signaling. Tulp3 knockout mice are embryonic lethal with developmental abnormalities in multiple organs, while tissue-specific knockouts and viable missense alleles cause polycystic kidney disease. Human patients with TULP3 mutations present with variable, but often multi-organ fibrotic disease. We previously showed that mouse and human Tulp3 expression is negatively regulated by ZNF423, which is required for SHH sensitivity in some progenitor cell models. The level of TULP3 function required to prevent mutant phenotypes has not been known. Here we report a Tulp3 quantitative allelic series, designed by targeting the polypyrimidine tract 5' to the splice acceptor of a critical exon, that shows distinct dose-response effects on viability, brain overgrowth, weight gain, and cystic kidney disease. We find limited evidence for genetic interaction with Zfp423 null or hypomorphic mutations. Together, these results establish an approach to developing quantitative allelic series by exon exclusion, rank-order dose-sensitivity of Tulp3 phenotypes, and model thresholds for TULP3 function to prevent severe outcomes.
Indexed as
BrainDNA-Binding ProteinsKidneyTranscription FactorsAllelesAnimalsHomeostasisHumansMiceMice, KnockoutMutationPhenotypeDNA-Binding ProteinsTranscription Factors
Identifiers
PMID41091799
PMCPMC12539727
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390